PRESS RELEASE – FIRST IN FLORIDA ACTIVATED FOR PASCAL TRANSCATHETER TRICUSPID VALVE REPAIR DEVICE AS PART OF THE CLASP II TR PIVOTAL TRIAL
FIRST IN FLORIDA- THE FLORIDA STRUCTURAL HEART DISEASE CENTER TOGETHER WITH THE CARDIAC & VASCULAR INSTITUTE RESEARCH FOUNDATION IS FIRST SITE ACTIVATED FOR PASCAL TRANSCATHETER TRICUSPID VALVE REPAIR DEVICE AS PART OF THE CLASP II TR PIVOTAL TRIAL
GAINESVILLE, FLORIDA March 15, 2021 – The Florida Structural Heart Disease Center at North Florida Regional Medical Center (NFRMC), together with The Florida Heart & Lung Institute (FHLI) and The Cardiac & Vascular Institute Research Foundation (TCAVIRF), have announced that they are the first site activated in the state of Florida in the Edwards Lifesciences PASCAL CLASP II TR Pivotal Clinical Trial. This clinical trial will evaluate the PASCAL transcatheter device for the management of patients with tricuspid regurgitation who have been determined to be at intermediate or greater risk for tricuspid valve surgery by the Structural Heart Team.
Continue reading here: PASCAL – Press Release – The Florida Structural Heart Disease March 2021